Global Health Otherwise/LinkedIn
Accelerating Clinical Trial Approvals Across <a href="https://absafricatv.com/the-uneven-path-to-high-speed-connectivity-in-west-africa/” title=”The Uneven Path to High-Speed Connectivity in West Africa”>Africa – Global Health Otherwise
Global Health Otherwise, shared onLinkedIn:
“Africa carries a fifth of the world’s population and a large share of global disease, yet the continent hosts just3% of clinical trials worldwide.
Fragmented regulatory systems have long slowed research and delayed access to safe treatments.
Wiysonge and colleagues (2026) offer a commentary tracing two decades of effort to fix this problem, from the African Vaccine Regulatory Forum launched in 2006 to the African Medicines Agency established in 2021.
The authors show that voluntary, consensus-based reviews collectively cut approval times from a year to about two months, speeding evaluations for vaccines against meningitis, malaria, Ebola, COVID-19, and mpox.
They argue that lasting progress depends on clear roles for WHO, Africa CDC, and the African Medicines Agency, stronger investment in regulatory workforce and infrastructure, and homegrown oversight of artificial intelligence tools in health products, built on African-led regulatory science.
Two decades of collaborative regulatory reform have accelerated Africa’s clinical trial approvals, but lasting progress now requires stronger governance, sustained investment, and African-led oversight of health technologies including artificial intelligence.”
Title: Strengthening regulation of clinical trials in Africa: a Strategic roadmap for health sovereignty
Authors: Charles S Wiysonge, Patrick D. M. C Katoto, Chinwe Iwu-Jaja, and Glenda E Gray
- New Paper Alert
Africa CDCAfrican Medicines Agencyand Glenda E Grayartificial intelligencecancerCharles S WiysongeChinwe Iwu-JajaCOVID-19EbolamalariaMeningitisOncoDailyOncologyPatrick D. M. C KatotoWiysonge
